Objective: To review the evidence for the role of long-acting injectable (LAI) antipsychotics (APs), especially the second-generation AP (SGA) LAIs, in the treatment of schizophrenia and to discuss the use rates of LAIs in Canada.
• LAIs may offer some advantage to patients with poor medication adherence in all phases of illness.
• LAIs are underused in Canada, suggesting a need for increased understanding of such underuse and corrective action.
Limitations
• The data on SGA LAIs are limited to only 2 currently available drugs (that is, RLAI and PLAI).
• RCTs are difficult to conduct with LAIs given the rigour of methodology; this may limit the types of patients recruited and such patients may not be representative of real-world patients.
• Outcome data with LAIs are highly influenced by the short-term nature of the studies and limited long-term data.
T he efficacy of the FGA LAIs is well established. 1 In contrast, the SGA LAIs were introduced in Canada relatively recently. The implicit objective of using LAIs as a treatment option is to address the ubiquitous problem of nonadherence to APs. 2 With the introduction and widespread claims of superior effectiveness and improved adherence of the oral SGAs in the early 1990s, the use of the FGA LAIs declined markedly. However, the initial claims of superior effectiveness and improved adherence of oral SGAs have not been borne out in more recent controlled and randomized studies. 3 Continuing concerns about poor adherence to medication among patients and the recent availability of long-acting formulations of SGAs have sparked a renewed interest in the use of LAIs in the long-term treatment of psychotic disorders.
Here, we review the evidence for the effectiveness of LAIs in different domains and their use rates, with special reference to practice patterns in Canada. We confine ourselves primarily to the SGA LAIs and oral APs for comparison. The objective is to contribute toward a knowledge base and provide rationale for recommendations for their use along with additional evidence reported in this supplement.
Methods
A literature search was conducted for the period from 1995 to 2012 using the following search engines: PubMed, PsycINFO, Web of Science, and Google Scholar. Search terms used in combination were "long-acting injectable," "risperidone," "antipsychotic," "depot medication" and "schizophrenia" or "psychosis" and "cost," "adverse effects," "hospitalization," "bias," "knowledge," "preference," "relapse," "remission," and "effectiveness." A separate search was also conducted with the terms "paliperidone palmitate" and "schizophrenia." Literature for inclusion was restricted to studies based on RCTs, highquality observational studies, meta-analyses (not all primary citations were reviewed), as well as expert and systematic literature reviews (levels of evidence 1 and 2). 4 In addition, expert consensus data were also solicited on LAI use within a Canadian context.
LAIs in Canada
In addition to 5 FGA LAIs (that is, fluphenazine decanoate, fluphenazine enanthate, haloperidol decanoate, zuclopenthixol decanoate, and flupenthixol decanoate), 2 SGA LAIs are currently available in Canada (that is, RLAI and PLAI).
Méthode : une recherche des bases de données médicales a été menée dans la littérature publiée (1995-2012) sur les effets des IAP sur les domaines de la rémission, l'observance, la rechute, et l'hospitalisation. Les résultats obtenus des essais randomisés contrôlés (ERC), des revues systématiques, des méta-analyses, et des études d'observation à grande échelle ont été inclus. Les données de consensus des experts ont aussi été sollicitées en ce qui concerne l'utilisation des IAP dans un contexte canadien. 
Résultats

Efficacy
Level 1 Evidence: RCTs, and Systematic and Meta-Analytic Reviews
The efficacy of the first SGA LAI, RLAI, was evaluated in 3 pivotal trials, 2 short-term (12 and 24 weeks) studies, comparing RLAI with placebo and RLAI with oral risperidone, respectively, and 1 long-term (52 weeks) study involving a switch of stable patients to RLAI. [5] [6] [7] An early Cochrane review of RLAI analyzed data from 2 of the pivotal trials and reported that RLAI, compared with placebo, reduced psychosis (RR 0.5; 95% CI 0.33 to 0.83; NNT 9; 95% CI 7 to 26) and agitation (RR 0.6; 95% CI 0.39 to 0.92), but did not substantially influence hallucinations (RR 1.23; 95% CI 0.47 to 3.22). 8 Overall drop-out rates were high but greater for placebo than RLAI (RR 0.74; 95% CI 0.63 to 0.88; z = 3.38, P < 0.001). Compared with oral risperidone, there was no clear differences in global outcomes (RR 1.06; 95% CI 0.92 to 1.22) or mental state measures in stable patients with mild illness.
The efficacy of the second SGA LAI available in Canada, PLAI, was evaluated in 4 short-term (one 9-week and three 13-week) double-blind, randomized, placebo-controlled, fixed-dose trials. [9] [10] [11] [12] A recently published Cochrane review found that, compared with placebo, PLAI-treated patients were significantly less likely to show no improvement in global state (RR 0.79; 95% CI 0.74 to 0.85; NNT 7; 95% CI 5 to 9), and less likely to experience a recurrence of psychosis, either in a specifically designed study (RR 0.28; 95% CI 0.17 to 0.48; NNT 5; 95% CI 4 to 6) or as an AE (RR 0.55; 95% CI 0.44 to 0.68; NNT 10; 95% CI 8 to 14). 13 Drop-out risk was lower with PLAI (RR 0.76; 95% CI 0.70 to 0.84; NNT 9; 95% CI 7 to 14) and there were fewer reports of agitation or aggression (RR 0.65; 95% CI 0.46 to 0.91; NNT 39; 95% CI 25 to 150).
A recent systematic review and meta-analysis of RCTs of both FGA and SGA LAIs of 12 months or more duration found that significantly fewer participants in the LAI group dropped out owing to inefficacy of treatment (LAIs 20.61%, orals 29.6%, n = 1380, RR 0.71; 95% CI 0.57 to 0.89, P = 0.002). 14 Conversely, a more recent meta-analysis of RCTs of LAI, compared with oral APs, reported no advantage of SGA LAIs, compared with oral SGAs, and concluded that studies in real-world patients were needed. 15 Evidence from less rigorous open-label and observational studies suggests that patients transitioning from oral FGAs or SGAs to RLAI experience significant improvement in symptoms. 16 This effect was observed particularly in previously nonadherent patients. 17, 18 Other similar studies of large samples [19] [20] [21] (range 1345 to 1876) show improvement on global measures, such as the Clinical Global Impression and the Global Assessment of Functioning. In addition, 2 open-label international studies with RLAI, have also reported a significant reduction in symptoms (PANSS) at 6 to 18 months. 22, 23 
LAIs and Remission
Symptomatic remission in schizophrenia, operationally defined as achieving a low to mild symptom intensity level (≤3) on 8 core PANSS items sustained for 6 months, 24 has been shown to be a primary determinant of functional outcome. 25 There have been few studies of SGA LAIs specifically examining their impact on remission as per the new criteria. In a post hoc analysis of patients in a longterm study switched from oral FGA, oral SGA, or an FGA LAI to RLAI (25, 50, or 75 mg), 82 (20.8%) previously nonremitted patients achieved remission, and 156 of the 184 patients who met remission criteria at baseline remained in remission after 1 year of treatment. 7, 18, 26 Similar results have been reported from other studies of RLAI. 22, 23, [27] [28] [29] 
LAIs and Adherence
The proportion of community patients with schizophrenia reported to be partially or totally nonadherent to oral APs ranges from 45% to 90%, with no differences evident between oral FGAs and oral SGAs. [30] [31] [32] [33] A meta-analysis of 5 RCTs with 1141 patients and variable criteria for measuring adherence suggested no significant difference in adherence between those on LAIs (FGA and SGA), compared with oral (FGA and SGA) APs. 14 This is contrary to the belief held by many psychiatrists that LAIs are associated with better adherence than oral APs. This dichotomy likely exists because nonadherence is a deliberate act, thus a different formulation of medication is unlikely to influence it and that patients participating in RCTs are more likely to be willing to take treatment and to be cooperative, thereby obscuring any observable differences.
LAIs and Relapse
Adams et al 34 searched the Cochrane Database and extracted data from RCTs of LAIs. There was no significant difference in relapse rates between LAIs and oral APs. A meta-analysis of only RCTs (n = 10) of 1 year or longer, involving 1672 participants, indicated a significant superiority of LAIs, compared with oral medications, in reducing relapse rates, with relative and absolute risk reductions of 10% to 30% and 10%, respectively. 14 In a recent meta-analysis 15 of 21 RCTs with 5176 patients, pooled LAIs did not reduce relapse, compared with oral APs, in patients with schizophrenia. Analyzing individual LAIs, only the FGA fluphenazine LAI showed significant superiority, compared with oral APs, specifically at 24 months.
For the SGA LAIs, relapse rates investigated in a 2-year RCT with RLAI (n = 329), compared with quetiapine (n = 337), showed a lower rate (16.5%) and longer time to relapse in the former group, compared with the latter (31.3%). 35 The Kaplan-Meier estimate of time-to-relapse was significantly longer with RLAI (P < 0.001). In the only published RCT placebo-controlled study with PLAI, timeto-relapse favoured PLAI (P < 0.001, log-rank test) at both interim and final analysis (n = 408). 36 Unfortunately, some patients with schizophrenia will relapse despite being adherent to medications, most likely owing to the nature of the illness, stress, or concurrent substance abuse. [37] [38] [39] Although it may be anticipated that LAIs provide better adherence than oral APs and hence better relapse prevention, this is not always evident in RCTs. Therefore, one would consider that the evidence favouring LAIs is not unequivocal.
LAIs and Hospitalization
In the meta-analysis by Leucht et al, 14 based on 7 RCTs (n = 1476), and by Kishimoto et al 15 there were no significant differences between LAIs, compared with oral APs, on rehospitalizations. Only fluphenazine LAI was superior to oral APs. 15 However, an a priori planned sensitivity analysis using a fixed-effects model found LAIs significantly superior to oral medication on rehospitalization for any reason. 14 The effect was particularly significant if the oral and LAI were the same drug. On the contrary, a subsequent single-blind RCT, conducted with 369 veterans with schizophrenia or schizoaffective disorder, failed to reveal any significant differences on rates of rehospitalization (45% and 39%) and time to hospitalization (10.8 and 11.3 months), respectively, between the oral APs and RLAI. 40 A recent pharmacoeconomic review of 17 studies, of varying methodologies (RCTs, mirror image, and large-scale open-label), during 6 to 24 months, reported reductions in hospitalization associated with RLAI, 26 although numerous analyses from 1 long-term UK cohort did not show such reduction. In another non-RCT study (n = 1345), RLAI showed greater reductions in the number (reduction of 0.37 stays per patient, compared with 0.2, P < 0.05) and days (18.74, compared with 13.02, P < 0.01) of hospitalizations at 24 months than for oral AP patients (n = 277). 41 Findings from a long-term, double-blind, randomized, multi-phase relapse prevention study (n = 213) indicated that treatment with PLAI from double-blind to end of OLE phase was associated with a significant decrease in the mean number of hospitalizations per person-year from 0.27 to 0.06 (78% reduction, P = 0.05) for patients treated with placebo in the double-blind phase, and an 88.6% reduction in hospitalization rates for patients (n = 381) from before enrolment to end of the OLE phase. 42 In a prospective observational study of patients with schizophrenia, comparing RLAI (n = 40) with FGA LAI (n = 54), hospital discharge rates were 33 (83%) and 31 (58%) and readmission rates of 0% and 26%, respectively. 43 In another year-long study, 397 patients, switched from their previous oral AP to RLAI (modal dose of 25 or 50 mg), required significantly fewer (12%, n = 48, compared with 38%, n = 150) hospitalizations in the last 3 months of treatment 48 (12%). 6 Olivares et al 41 found that patients treated with RLAI (n = 1345) had significantly reduced rates of hospitalization, compared with those receiving oral APs (n = 277) along with a greater reduction in the mean number of days hospitalized in the RLAI, compared with oral risperidone group. Patients from 8 Canadian clinical sites who switched from their previous oral medication to RLAI (25, 50, or 75 mg) were significantly less likely to be hospitalized in the postswitch period (41.5 months), compared with an identical period (40.8 months) prior to use (50.7% and 4.3%, respectively). Duration of hospitalization also significantly decreased from 23.5 to 0.3 days per patient following the switch. 44 Meta-analysis of RCTs show superiority only for fluphenazine LAI, compared with oral APs, and pooled LAIs show trend-level superiority, compared with oral APs. The findings of a nationwide cohort study of oral APs and depot APs after first hospitalization for schizophrenia carried out in Finland deserves mention. 45 Among 2588 patients, 1406 (54.3%) either did not collect an AP prescription within 30 days of hospital discharge or used their initial APs for less than 30 days. In a pairwise comparison between depot injections and their equivalent oral formulations, the risk of rehospitalization for patients receiving depot medications was about one-third of that for patients receiving oral medications. The authors emphasize that observational studies are the only way to investigate this issue as nonadherent patients cannot be forced to participate in RCTs.
HRQoL and Functioning With LAIs
The evidence of any differential impact on HRQoL from SGA LAIs and oral APs would, on the whole, be considered equivocal, despite some favourable results for LAIs from methodologically less rigorous studies. RCTs have generally failed to find any significant differences between groups using oral APs and RLAI on quality of life or on global functioning. 40 However, a post hoc analysis from a multicentre, placebo-controlled trial showed that 277 patients receiving RLAI (25, 50, or 75 mg) for 12 weeks showed significant improvements in 5 domains of the Short-Form Health Survey (that is, bodily pain, general health perceptions, social role functioning, emotional role functioning, and mental health), compared with the 92 placebo-treated patients. 28 In an observational study of a nonadherent patient population switched to RLAI, significant improvements on the Person and Social Performance Scale (60.0 to 69.1, P < 0.001) and the Drug Attitude Inventory Scale (from 2.78 to 5.07, P = 0.006) 17 were reported. It is unlikely that differences in HRQoL, not attributable to improvement in symptoms, can be detected between 2 treatments during a relatively short period of time and its clinical relevance remains unknown.
LAIs and AEs
Studies comparing RLAI with placebo suggest a low discontinuation rate owing to AEs (range 1.2% to 13%). 46 The most common AEs include headaches (range 7% to 28%), insomnia (range 7% to 28%), anxiety (range 7% to 24%), and psychosis (range 5% to 31%). 29 In a 12-month, multicentre, open-label switch study of nonadherent patients (n = 51), the most frequent AEs were insomnia (22.6%), increased prolactin (17.0%), and weight gain (13.2%). 17 In a short-term (12-week), double-blind, placebo-controlled study, patients randomized to receive RLAI gained a mean of 0.5, 1.2, and 1.9 kg in the 25, 50, and 75 mg groups, compared with a loss of 1.4 kg in the placebo group. 5 Data from other studies of RLAI of varying lengths suggest modest weight gain (mean 1.8 kg) with a dose of 25 mg and a low occurrence of dyslipidemia or hyperglycemia. 29, 47 PLAI causes comparable weight gain and elevation in prolactin levels to RLAI. 10 AEs that were more frequently reported by patients receiving PLAI, compared with placebo groups, included insomnia, headache, dizziness, sedation, vomiting, schizophrenia, injection site pain, extremity pain, myalgia, and EPSs. [47] [48] [49] In RCTs, dose-dependent EPSs have been reported with RLAI, comparable to placebo, for the 25 mg dose (13% and 10%, respectively), 5 but higher than with oral SGAs. 28 There is a low annual risk of tardive dyskinesia with RLAI, 50 which is comparable to that of oral risperidone 51 and other oral SGAs, [52] [53] [54] while data from an observational study reported a decrease in baseline dyskinesia. 55 SGA LAIs, such as RLAI and PLAI, do not use an oil vehicle as their base and, with proper administration, there may be less risk of certain injection site complications.
LAIs and Early Phase of Psychotic Disorders
Relatively few studies have examined the effectiveness and clinical utility of LAIs in the early phase of psychotic disorders, despite very high rates of nonadherence during this phase and a high risk of relapse, mostly consequent on nonadherence to medication. 56 In a single-site, prospective, open-label study comparing RLAI and oral risperidone or haloperidol, 50 patients with FEP (36 completed full trial), following a medication wash-out period and an oral runin period with risperidone, were switched to RLAI (25 to 50 mg). 57, 58 Compared with patients treated with oral risperidone or haloperidol, RLAI-treated patients had significantly fewer all-cause discontinuations (26.0% and 70.2%, respectively, at 24 months, P < 0.005), greater reduction on PANSS total scores (-39.7 and -25.7, respectively; P = 0.009), higher rate of remission of positive symptoms (64.0% and 40.4%, respectively; P = 0.03), and lower relapse rate (9.3% and 42.1%, respectively; P = 0.001) among the responders. 58 Among patients who achieved remission of positive symptoms at some point during the study (n = 32; 64%), 97% (n = 31) remained in remission to completion. The relative paucity of long-term data in patients with FEP makes it difficult to determine the most appropriate use of LAIs in this population. The study by Tiihonen et al 45 (reported earlier in the LAIs and Hospitalization section) further supports using LAIs in early psychosis.
Use of LAIs in Canada
The frequency of the use of LAIs in predominantly outpatient samples of people with psychotic disorders from different countries (1996-2007) ranged from 6.3 to 80% (Table 1) . 1, 7, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] A Canadian study 61 reported that, across all patient types, only 6.3% were receiving LAIs, with rates varying across provinces: British Columbia (12.5%), Maritimes (7.6%), Prairies (6.6%), Alberta (5.7%), Ontario (3.1%), and Quebec (2%). We obtained Canadian data from IMS Health regarding the overall use of oral and LAI by province, which showed that use of LAIs nationally (FGA and SGA) in 2011 was 2.4% ( Table 2 ). In a survey from England of 102 psychiatrists, 50% reported a decrease in LAI use during the previous 5 years, with 27% indicating no change and 24% reporting an increase. 1 Only a minority (4%) of psychiatrists rated LAIs (FGA or SGA) as a first choice preference for long-term maintenance of schizophrenia, and instead, most preferred to use oral SGAs. This would suggest that most psychiatrists today prefer to prescribe oral SGAs, despite the availability of SGA LAIs. Following a failure of oral SGAs to improve rates of nonadherence and hence rates of relapse and remission, the SGA LAIs may reignite an interest in the use of LAIs as a treatment modality, but little information is available regarding the frequency of use of SGA LAIs.
In Canada, LAI use also appears to vary according to the clinical setting and the stage of illness being treated. 
Conclusions
Improving outcome in schizophrenia and related psychotic disorders, while challenging, is a major goal of treatment.
A relatively large proportion of variance in outcome is associated with potentially modifiable factors, of which nonadherence or partial adherence to treatment is one of the most common and difficult to address. Further, nonadherence is associated with lower rates of remission, higher rates of relapse, hospitalization, and (or) continued disability, as well as higher rates of medical morbidity and mortality from all causes. Achieving remission, and sustaining it for long periods, is critical for improving social and occupational functioning, especially in the early phase of the illness, when patients are more likely to show the greatest change in level of functioning, but, simultaneously, most likely to be nonadherent to medication.
The overall evidence discussed here, while not entirely convincing of the superiority of LAIs, compared with oral medications, especially if based on RCTs alone, is suggestive of equal effectiveness and some benefits of using LAIs in patients likely to be, and remaining, nonadherent, irrespective of the phase of the illness. In fact, while LAIs may not prevent nonadherence (because a patient can refuse the injection), their use does potentially allow for earlier recognition of nonadherence whenever a dose is missed, and thus to be able to distinguish between non-or poor responsiveness from non-or partial adherence.
In contrast to RCTs, recent naturalistic studies support the advantages of LAIs, compared with oral APs. [73] [74] [75] These findings deserve merit as patients consenting to participate in RCTs of LAIs may not be representative of those prescribed LAIs in real-world settings. 76 In clinical practice, the uncooperative and nonadherent patients who are the most likely to get a benefit specific from the longacting mode of administration are underrepresented in such studies. Further, the increased intensity of service generally provided during RCTs probably also contributes to increased adherence in patients treated with oral medication. Hence RCTs may underestimate the benefits from LAIs. 77 Given the costs incurred from hospitalization and care (79% of direct costs), compared with medication use (1% to 6%), the focus should be on using different medications that will increase adherence and eventually result in overall savings. 78 However, one cannot entirely overlook the costs associated with as SGA LAIs, compared with FGA LAIs, as barriers to prescribing. The ultimate decision should be based on a patient's preference, tolerability, AE experience, and the prescriber's comfort level. For patients who are clearly adherent to oral APs, there may be no reason or evidence to advocate a switch to LAIs. In any case, the relatively low use of LAIs in Canada needs to be better understood and addressed so as to make an effective treatment more readily available to a larger proportion of patients with psychotic disorders, especially when covert nonadherence is suspected.
